Kevin Koch, Ph.D.

Kevin Koch, Ph.D.

President and Chief Executive OfficeratEdgewise Therapeutics· In proxies 2022–2025

Pay in FY2025-3% from the year before · Edgewise Therapeutics stock -7.1% the same year

Kevin Koch, Ph.D. was paid $7.4M in FY2025 (Dec), down 3%. Edgewise Therapeutics stock fell 7.1% that year.

Pay$100 in the stock at the end of FY21 → $162
Pay is from the Summary Compensation Table of each Edgewise Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Edgewise TherapeuticsPublic company · 4 yr
    • President and Chief Executive Officer2022 – Present · 4 yrStock in role +181%
  2. Neurogastrx, Inc.Public company
    • Director? – PresentNo stock prices for these years
  3. Miragen Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years
  4. Terremoto BiosciencesPublic company · 2 yr
    • Director2021 – 2023 · 2 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Edgewise TherapeuticsDirector · 8 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?